Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BaxAsia: baxdrostat in uncontrolled hypertension including resistant hypertension
CTR20241008Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of baxdrostat in hypertension (HTN), resistant hypertension (RH), sponsored by AstraZeneca. Started May 2024; status: completed.
02
Drugs
baxdrostat
03
Conditions
hypertension (HTN)resistant hypertension (RH)
Beyond the preview
Go deeper on CTR20241008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241008.